These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 19126937)
21. [Effects of iloprost combined with low dose tadalafil in adult congenital heart disease patients with severe pulmonary arterial hypertension: a single-center, open-label controlled study]. Zhang C; Huang Y; Huang T; Xia C; Huang X; Zhang G; Yao H; Chen J; Chen J; Wu S; Zhuang J Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jun; 42(6):474-80. PubMed ID: 25164220 [TBL] [Abstract][Full Text] [Related]
22. Tadalafil improves oxygenation in a model of newborn pulmonary hypertension. Tessler RB; Zadinello M; Fiori H; Colvero M; Belik J; Fiori RM Pediatr Crit Care Med; 2008 May; 9(3):330-2. PubMed ID: 18446109 [TBL] [Abstract][Full Text] [Related]
23. Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. Wong RC; Koh GM; Choong PH; Yip WL Int J Cardiol; 2007 Jul; 119(3):400-2. PubMed ID: 17064789 [TBL] [Abstract][Full Text] [Related]
24. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Barst RJ; Oudiz RJ; Beardsworth A; Brundage BH; Simonneau G; Ghofrani HA; Sundin DP; Galiè N; J Heart Lung Transplant; 2011 Jun; 30(6):632-43. PubMed ID: 21256048 [TBL] [Abstract][Full Text] [Related]
25. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Jing ZC; Jiang X; Wu BX; Xu XQ; Wu Y; Ma CR; Wang Y; Yang YJ; Pu JL; Gao W Heart; 2009 Sep; 95(18):1531-6. PubMed ID: 19549620 [TBL] [Abstract][Full Text] [Related]
26. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Schiopu E; Hsu VM; Impens AJ; Rothman JA; McCloskey DA; Wilson JE; Phillips K; Seibold JR J Rheumatol; 2009 Oct; 36(10):2264-8. PubMed ID: 19755613 [TBL] [Abstract][Full Text] [Related]
27. The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' VO2max, aerobic, and anaerobic thresholds in normoxia. Di Luigi L; Baldari C; Pigozzi F; Emerenziani GP; Gallotta MC; Iellamo F; Ciminelli E; Sgrò P; Romanelli F; Lenzi A; Guidetti L Int J Sports Med; 2008 Feb; 29(2):110-5. PubMed ID: 17614028 [TBL] [Abstract][Full Text] [Related]
28. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Goudie AR; Lipworth BJ; Hopkinson PJ; Wei L; Struthers AD Lancet Respir Med; 2014 Apr; 2(4):293-300. PubMed ID: 24717626 [TBL] [Abstract][Full Text] [Related]
29. Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. Incrocci L; Slob AK; Hop WC Urology; 2007 Dec; 70(6):1190-3. PubMed ID: 18158045 [TBL] [Abstract][Full Text] [Related]
30. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Affuso F; Palmieri EA; Di Conza P; Guardasole V; Fazio S Int J Cardiol; 2006 Apr; 108(3):429-31. PubMed ID: 16260051 [TBL] [Abstract][Full Text] [Related]
31. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema. Fischler M; Maggiorini M; Dorschner L; Debrunner J; Bernheim A; Kiencke S; Mairbäurl H; Bloch KE; Naeije R; Brunner-La Rocca HP Am J Respir Crit Care Med; 2009 Aug; 180(4):346-52. PubMed ID: 19520908 [TBL] [Abstract][Full Text] [Related]
32. Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use? Chapman TH; Wilde M; Sheth A; Madden BP Vascul Pharmacol; 2009; 51(2-3):90-5. PubMed ID: 19386283 [TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. Xu XQ; Jing ZC; Zhang JH; Wu Y; Wang Y; Jiang X; Wang ZX; Sun YG; Pu JL; Yang YJ Hypertens Res; 2009 Oct; 32(10):911-5. PubMed ID: 19644505 [TBL] [Abstract][Full Text] [Related]
34. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Madden BP; Allenby M; Loke TK; Sheth A Vascul Pharmacol; 2006 May; 44(5):372-6. PubMed ID: 16574495 [TBL] [Abstract][Full Text] [Related]
35. One year efficacy and safety of oral sildenafil treatment in severe pulmonary hypertension. Samarzija M; Zuljević E; Jakopović M; Sever B; Knezević A; Dumija Z; Vidjak V; Samija M Coll Antropol; 2009 Sep; 33(3):799-803. PubMed ID: 19860106 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Chockalingam A; Gnanavelu G; Venkatesan S; Elangovan S; Jagannathan V; Subramaniam T; Alagesan R; Dorairajan S Int J Cardiol; 2005 Mar; 99(1):91-5. PubMed ID: 15721505 [TBL] [Abstract][Full Text] [Related]
37. Tadalafil for the treatment of pulmonary arterial hypertension. Klinger JR Expert Rev Respir Med; 2011 Jun; 5(3):315-28. PubMed ID: 21702653 [TBL] [Abstract][Full Text] [Related]
38. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Zhuang Y; Jiang B; Gao H; Zhao W Hypertens Res; 2014 Jun; 37(6):507-12. PubMed ID: 24646647 [TBL] [Abstract][Full Text] [Related]
39. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768 [TBL] [Abstract][Full Text] [Related]